Gastrointestinal Cancer

Salvage Regorafenib Emphasizes Need for Nuanced Treatment Selection in Metastatic CRC

October 09, 2021

An expert from The University of Texas MD Anderson Cancer Center recently highlighted the ramifications of the phase 2 ReDOS trial, the need for molecular profiling in mCRC, and ongoing research on the combination of TKIs and checkpoint inhibitors.